StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX)

Equities researchers at StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Price Performance

DURECT stock opened at $0.90 on Tuesday. The firm has a market cap of $28.05 million, a price-to-earnings ratio of -1.48 and a beta of 1.13. The firm has a fifty day moving average price of $1.31 and a two-hundred day moving average price of $1.37. DURECT has a fifty-two week low of $0.48 and a fifty-two week high of $1.88.

Hedge Funds Weigh In On DURECT

Several large investors have recently bought and sold shares of the stock. International Assets Investment Management LLC increased its holdings in shares of DURECT by 41.3% during the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock worth $28,000 after purchasing an additional 6,300 shares during the period. Accredited Investors Inc. acquired a new stake in DURECT during the second quarter worth about $113,000. Geode Capital Management LLC increased its stake in DURECT by 4.8% during the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 14,658 shares during the period. Finally, Richmond Brothers Inc. raised its holdings in DURECT by 39.5% in the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock valued at $1,383,000 after acquiring an additional 303,670 shares in the last quarter. 28.03% of the stock is currently owned by institutional investors and hedge funds.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.